1. Generics Bulletin

Mylan has rival to Exelon in US

Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).

Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).

Citing Iqvia data, Mylan observed that the rivastigmine transdermal system in the three doses had US sales of approximately US$248...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By Dave Wallace

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 
• By Urtė Fultinavičiūtė

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By Dean Rudge

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.